» Articles » PMID: 34402023

Co-delivery Systems: Hope for Clinical Application?

Overview
Publisher Springer
Specialty Pharmacology
Date 2021 Aug 17
PMID 34402023
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is a multidimensional and challenging disease to handle. Current statistics reveal that we are far from satisfying cancer treatment. Taking advantage of different therapeutic agents that affect multiple pathways has been established as highly productive. Nevertheless, owing to several hindrances to conventional combination therapy, such as lack of tumor targeting, non-uniform pharmacokinetic of the combined drugs, and off-target side effects, it is well documented that this treatment approach is unlikely to address all the difficulties observed in monotherapy. Co-delivery systems could enhance the therapeutic efficacy of the combination therapy by targeting cancer cells and improving the pharmacokinetic and physicochemical properties of the therapeutic agents. Nevertheless, it seems that present knowledge in responding to the challenges in cancer treatment is still inadequate and far from optimal treatment, which highlights the urgent need for systematic studies direct to identify various aspects of co-delivery systems. Accordingly, to gather informative data, save time, and achieve superior results, the following steps are necessary: (1) implementing computational methods to predict drug-drug interactions (DDIs) in vitro and in vivo, (2) meticulous cancer studies at the cellular and molecular levels to obtain specific criteria for selecting preclinical and clinical models, (3) extensive physiological and pharmacokinetic study of nanocarriers behavior in preclinical models, and (4) finding the optimal formulation and analyzing its behavior in cellular and animal models facilitates bridging in vivo models to clinical trials. This review aims to deliver an overview of co-delivery systems, rationales, and suggestions for further studies in this field.

Citing Articles

Combinational Antitumor Strategies Based on the Active Ingredients of Toad Skin and Toad Venom.

Tian H, Zhao F, Yue B, Zhai B Drug Des Devel Ther. 2024; 18:3549-3594.

PMID: 39139676 PMC: 11321342. DOI: 10.2147/DDDT.S469832.


Harnessing exosomes in theranostic applications: advancements and insights in gastrointestinal cancer research.

Shojaeian A, Naeimi Torshizi S, Parsapasand M, Amjad Z, Khezrian A, Alibakhshi A Discov Oncol. 2024; 15(1):162.

PMID: 38743146 PMC: 11093943. DOI: 10.1007/s12672-024-01024-x.


Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy.

Zhang M, Fang L, Guo Y, Wang Q, Li Y, Sun H Int J Nanomedicine. 2024; 19:3387-3404.

PMID: 38617801 PMC: 11012697. DOI: 10.2147/IJN.S454004.


Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study.

Cao Q, Zhu J, Wu X, Li J, Chen Y, You Y J Cancer. 2024; 15(7):2024-2032.

PMID: 38434976 PMC: 10905414. DOI: 10.7150/jca.92624.


Research Progress of SN38 Drug Delivery System in Cancer Treatment.

Qi Q, Tian H, Yue B, Zhai B, Zhao F Int J Nanomedicine. 2024; 19:945-964.

PMID: 38293612 PMC: 10826519. DOI: 10.2147/IJN.S435407.


References
1.
Halsted W . I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. Ann Surg. 1907; 46(1):1-19. PMC: 1414357. DOI: 10.1097/00000658-190707000-00001. View

2.
Murthy S, Goldschmidt R, RAO L, Ammirati M, Buchmann T, SCANLON E . The influence of surgical trauma on experimental metastasis. Cancer. 1989; 64(10):2035-44. DOI: 10.1002/1097-0142(19891115)64:10<2035::aid-cncr2820641012>3.0.co;2-l. View

3.
Demicheli R, Retsky M, Hrushesky W, Baum M, Gukas I . The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008; 19(11):1821-8. DOI: 10.1093/annonc/mdn386. View

4.
Coffey J, Smith M, Wang J, Bouchier-Hayes D, Cotter T, Redmond H . Cancer surgery: risks and opportunities. Bioessays. 2006; 28(4):433-7. DOI: 10.1002/bies.20381. View

5.
Zhou Z, DEmanuele A, Attwood D . Solubility enhancement of paclitaxel using a linear-dendritic block copolymer. Int J Pharm. 2013; 452(1-2):173-9. DOI: 10.1016/j.ijpharm.2013.04.075. View